Siemens Healthineers started carving out its diagnostics unit as Olyrian Diagnostics on November 5, 2026, after the unit’s margin fell to 3.2% in fiscal 2026.
Last updated: November 8, 2026
Siemens Healthineers said on November 5, 2026 that it has started the carve out of its in vitro diagnostics business, which will become a standalone company called Olyrian Diagnostics by mid 2028. The unit earned an adjusted EBIT margin of just 3.2% in fiscal 2026.
This page covers the Olyrian announcement, the fiscal 2026 numbers behind it, and what the separation means for lab customers, suppliers and competitors.
What did Siemens Healthineers announce on November 5?
Siemens Healthineers said it has initiated the carve out process for its in vitro diagnostics business and that the unit will operate as a standalone company under the name Olyrian Diagnostics. The company expects the transition to be completed by mid 2028, and the business stays inside Siemens Healthineers until then.
The announcement came the same morning as fourth quarter fiscal 2026 results, and it arrived as a package. The parent also said it will change its own name to Healthineers, a proposal that needs approval at the annual shareholders’ meeting in February 2027, with a brand migration starting in 2027 and running over a three year transition. Both moves sit against the planned deconsolidation of Siemens AG’s stake in Siemens Healthineers, which the company referenced in its results release.
For customers, the company was explicit that nothing changes yet: as of the announcement, there is no change to products and services, contracts, service levels or customer points of contact, and the Olyrian name will roll out in stages. The business covers laboratory and point of care testing, and Siemens Healthineers says it manufactures more than 16 billion tests a year. Siemens acquired the businesses that make up the unit in 2006 and 2007.
What the company did not say matters as much. Neither release names a legal structure. There is no mention of a spinoff to shareholders, a sale, or an IPO; the language is “carve out” and “standalone organization.” That leaves every exit route open, and it is the first thing buyers, partners and lab customers will want answered.
Why is Siemens Healthineers separating its diagnostics business?
The short answer is in the numbers. Diagnostics revenue fell 4.8% on a comparable basis in fiscal 2026 to €4,029 million, and adjusted EBIT dropped 61.7% to €128 million. The group as a whole grew comparable revenue 4.0% and earned a 16.2% adjusted EBIT margin, so diagnostics was diluting a business that otherwise performs well.
| Diagnostics segment (€ millions) | FY2026 | FY2025 | Change |
|---|---|---|---|
| Adjusted revenue | 4,029 | 4,347 | −7.3% actual, −4.8% comparable |
| Adjusted EBIT | 128 | 333 | −61.7% |
| Adjusted EBIT margin | 3.2% | 7.7% | −4.5 points (our arithmetic) |
| Free cash flow | 2 | 79 | Near zero |
| Capital expenditure | 321 | 387 | Lower |
| Q4 adjusted EBIT margin | 5.4% | 7.5% | Improving within the year, still below prior year |
Source: Siemens Healthineers Q4 FY2026 quarterly statement. Group revenue was €23,630 million, so diagnostics was about 17% of sales (our arithmetic) while contributing roughly 3% of the group’s €3,823 million adjusted EBIT (our arithmetic).
The company pointed to China as the main drag: the region recorded a sharp revenue decline, which Siemens Healthineers attributed mainly to “a structural change in the market environment.” Restructuring charges in the fourth quarter (€92 million) included costs tied to the transformation and to preparing the carve out. Chief executive Bernd Montag framed the move as portfolio sharpening, saying in the results release that the company is “further strengthening our core, while positioning our Diagnostics business for a successful future.”
On the earnings call, as reported by MedTech Dive, Montag said the company has “started the carve out with a clear intention to separate,” and management discussed an additional €400 million savings target at the diagnostics unit and more than €300 million of stranded costs linked to the carve out, the ultrasound refocus and deconsolidation. Those figures come from MedTech Dive’s account of the call; we did not find them in the company’s written releases.
What does this mean for labs and hospital customers?
Nothing changes on day one, but procurement teams should start planning now. A diagnostics vendor going standalone typically changes three things customers feel: the contracting entity, the service organization, and the investment priorities behind the menu.
Reagent rental and analyzer contracts usually run for several years. A lab signing or renewing a Siemens Healthineers diagnostics contract in 2027 is signing with a business whose owner and balance sheet may look different before the term ends. The practical moves are to ask for assignment and change of control language, service level commitments that survive a change of ownership, and clarity on which entity carries warranty and uptime obligations.
Sharon Bracken, head of diagnostics, said Olyrian is “how we’ll define our next chapter.” For a lab director, the more useful signal will be the first standalone capital plan: which platforms get investment, and which get maintained.
How does Olyrian compare with other medtech separations this year?
Olyrian joins a run of large medtech and diagnostics separations in 2026. The pattern is consistent: conglomerates are shedding slower growth or lower margin units so the remaining business can be valued on its strongest franchise.
| Company | Unit | Status | Timing |
|---|---|---|---|
| Siemens Healthineers | In vitro diagnostics (Olyrian Diagnostics) | Carve out started; structure not disclosed | Completion expected by mid 2028 |
| Abbott | Nutrition (about $8.5 billion) | Announced spinoff | Independent company by end of 2027 |
| Medtronic | MiniMed (diabetes) | Completed; Medtronic exited its remaining stake | October 15, 2026 |
| BD | Biosciences and Diagnostic Solutions (combined with Waters) | Completed | February 9, 2026 |
Sources: company releases as covered in our reporting linked below.
The BD comparison is the sharpest. Two of the biggest diversified device makers have now moved diagnostics out of the core within a year. Our read: the market is rewarding focused device franchises and punishing mixed portfolios where a low margin, high volume testing business sits next to capital equipment and imaging.
Our framework: what to check before signing with a carve out vendor
- Contract assignment. Confirm whether the agreement can transfer to a new entity without your consent, and add change of control protections if it can.
- Service continuity. Get uptime, field service response and parts commitments in writing that bind successors.
- Platform roadmap. Ask which analyzers and assays are committed for continued development through 2030.
- Reagent pricing. Lock escalators for the full term, since a standalone business may reprice to rebuild margin.
- IT and connectivity. Check who owns middleware, LIS interfaces and cybersecurity patching after separation.
- Exit options. Keep a termination right tied to material service degradation.
What to watch next
- The legal structure: spinoff, sale, or listing. The company has not said.
- February 2027 annual shareholders’ meeting: the vote on the Healthineers name.
- Siemens AG’s deconsolidation of its stake and the parent’s new shareholder structure.
- Whether diagnostics revenue in China stabilizes; Montag said on the call that sales “stabilized sequentially while still declining,” per MedTech Dive.
- Fiscal 2027 guidance excludes portfolio measures: comparable revenue growth of 4% to 5% and adjusted EPS of €2.20 to €2.40 for the group.
Frequently asked questions
What is Olyrian Diagnostics?
Olyrian Diagnostics is the new name for Siemens Healthineers’ in vitro diagnostics business, which covers laboratory and point of care testing. Siemens Healthineers announced it on November 5, 2026 and expects the unit to be standalone by mid 2028.
Is Siemens Healthineers selling its diagnostics business?
The company has not said. It describes the move as a carve out to create a standalone company and has not disclosed whether that will be a spinoff, a sale or a listing.
When will the Olyrian separation be completed?
Siemens Healthineers expects the transition to be completed by mid 2028. Until then, Olyrian remains part of Siemens Healthineers.
How big is Siemens Healthineers’ diagnostics business?
Adjusted revenue was €4,029 million in fiscal 2026, which ended September 30, 2026, down 4.8% on a comparable basis. That is about 17% of group revenue, by our arithmetic.
How profitable is the diagnostics unit?
Its adjusted EBIT margin was 3.2% in fiscal 2026, down from 7.7% a year earlier. The fourth quarter margin was 5.4%.
Why did diagnostics revenue fall?
Siemens Healthineers said the China region recorded a sharp revenue decline, mainly due to a structural change in the market environment.
Will my Siemens Healthineers lab contracts change?
Not yet. The company said there is no change to products, services, contracts, service levels or customer contacts as of the announcement. Contracts running past 2028 deserve a review of assignment terms.
Is Siemens Healthineers changing its own name?
Yes. It plans to become Healthineers, subject to approval at the February 2027 annual shareholders’ meeting, with a three year brand migration starting in 2027.
Sources
Primary: Siemens Healthineers press release, “Olyrian Diagnostics,” November 5, 2026 (release); Siemens Healthineers Q4 FY2026 results release and quarterly statement, November 5, 2026 (release).
Attributed: MedTech Dive, “Siemens Healthineers to rebrand and separate its IVD business,” November 6, 2026 (earnings call quotes, €400 million savings target and stranded cost figure). Percentages marked as ours are our arithmetic from company figures.
Related coverage
- Abbott will spin off its $8.5 billion Nutrition business
- Medtronic completed the MiniMed separation
- CVS splits in two: what it means for Caremark and drugmakers
- The medical device companies to know in 2026
- Medicare cuts 340B drug pay in the outpatient rule
- BioMed Nexus company directory
Get our daily briefing: subscribe to BioMed Nexus.
